Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma

NCT04156958 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Adenocarcinoma

Interventions

DRUG: Fruquintinib

Sponsor

Sichuan University